United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

United Therapeutics is also proud to sponsor ... beginning to reveal clues that could help to efficiently detect pulmonary hypertension associated with interstitial lung disease,” said Andrew ...

DelveInsight's Pulmonary Arterial Hypertension Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 9, 2025 ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

I am once again making MannKind Corp. (MNKD) my "Top Pick" for more aggressive investors in 2025, advises Nate Pile, editor of Nate’s Notes.

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics (UTHR – Research Report) on January 21. The company’s shares ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of ...

HB Wealth Management LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The ...